Beyond the Conference Floor: Solving the Real-World Complexities of Rheumatology Trials at EULAR 2026 and Beyond
CISYS LifeSciences isn't attending EULAR 2026 in London, but we support rheumatology research year-round with tools for eligibility, adjudication, collaboration, and coding.
As the global rheumatology community gathers at ExCeL London for EULAR 2026, the conversations on the floor will naturally focus on the latest breakthrough efficacy data in rheumatoid arthritis, lupus, and psoriatic arthritis. But behind those scientific milestones sits a complex operational reality: running autoimmune and musculoskeletal studies across international sites is notoriously difficult.
CISYS LifeSciences won't have a physical booth in London this week, but our work alongside global CROs and emerging biotech sponsors doesn’t pause for conference season. We know the friction points that slow these studies down—from inconsistent site workflows and database bottlenecks to complex diagnostic criteria.
Whether you are navigating the sessions in London or following the science from your desk, achieving clinical success requires bridging the gap between rigorous scientific protocols and day-to-day site execution.
The Stakes of Diagnosis-Based Patient Selection in Rheumatology
In clinical research, selecting the right patient for the right study is one of the most critical determinants of trial quality, patient safety, and operational success. This is particularly true in rheumatology, where eligibility criteria are exceptionally intricate. Protocol compliance depends on a precise mix of symptom duration, lab thresholds, imaging reads, prior biologic exposure, and clinician assessments.
When eligibility relies on such a precise diagnosis, a superficial review of site-submitted information isn't enough. Getting patient selection wrong introduces significant risk: protocol deviations, delayed enrollment, inconsistent data, and avoidable burden on thin study teams.
To protect data integrity and reduce subjective variation across dozens of global sites, modern protocols require a disciplined, prospective pre-randomization review process. Rather than relying solely on local interpretation at the site level, this model introduces a formal, centralized verification step before a patient is approved for randomization.
However, the value of a prospective review depends entirely on how it is operationalized. If case packets are assembled manually across disconnected email chains and spreadsheets, decision-making stalls. Sites are left waiting, reviewers spend too much time tracking missing info, and sponsors lose momentum.
How the Sequence Platform Optimizes the Rheumatology Lifecycle
The CISYS Sequence Platform replaces fragmented, manual processes with a coordinated digital workflow designed specifically for complex trial demands. It is an integrated suite built around a shared data model and consistent user experience, allowing your teams to maintain speed without sacrificing scientific rigor.
Here is how Sequence supports your rheumatology study from first screen to final database lock
1. WebPatient: Eligibility Simplified
WebPatient addresses the exact challenge of prospective, pre-randomization review. It standardizes the review process across all global sites using intelligent, configurable forms that guide staff through precise protocol criteria. Centralized tracking gives your team real-time visibility into every pending case, ensuring fast, protocol-compliant enrollment decisions.
- The Impact: Transitioning from manual tracking to WebPatient’s coordinated digital workflow drives measurable performance gains, including an improved time from screening to randomization approval of 5 days, a 40% reduction in manual effort, and a site approval rating of 86%.
2. WebEAS: Confident Adjudication of Complex Endpoints
Rheumatology endpoints- including DAS28, ACR response, CDAI, joint counts, and imaging reads- require structured, blinded adjudication. WebEAS provides a secure workspace for your endpoint adjudication committee. Cases route automatically based on protocol rules, and independent reviews are captured in a fully auditable environment. The result is cleaner data packages, faster committee cycles, and a complete audit trail ready for regulatory review.
3. WebFXP: Sponsor-Site Communication Without the Chaos
Keeping global sites aligned on protocol amendments, data clarifications, and training updates shouldn't stretch your team across fragmented email threads. WebFXP replaces the inbox with a structured collaboration hub. Queries, documents, and announcements are organized by study, site, and subject. Your teams stay aligned, sites stay informed, and inspectors see a fully timestamped, GCP-compliant history.
4. WebCode: Medical Coding That Keeps Pace With Your Data
Autoimmune trials generate high volumes of adverse events and concomitant medications requiring precise MedDRA and WHODrug coding. WebCode accelerates this workflow with intelligent auto-suggest, coding history reuse, and configurable approval workflows. Verbatim terms are mapped consistently from the start, cutting rework during data review and compressing the timeline between the last patient visit and database lock.
Ready When You Are
You do not need to replace your existing EDC to benefit from these operational advancements. WebPatient, WebEAS, WebFXP, and WebCode are designed to integrate seamlessly into the environments your teams already use.
If your teams are in London this week discussing what is next in RA, lupus, PsA, or axSpA, we want to help turn those scientific advancements into operational success. Reach out before, during, or after EULAR 2026 to learn how we can optimize your upcoming trials.
